Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
J Allergy Clin Immunol Pract ; 11(8): 2557-2567.e6, 2023 08.
Article En | MEDLINE | ID: mdl-37182569

BACKGROUND: A guideline identifying when inpatients with penicillin or cephalosporin antibiotic allergy labels (PCAAL) can receive ß-lactam antibiotics increased ß-lactam receipt at a large northeastern US health care system. OBJECTIVE: To report outcomes of implementing a similar guideline and electronic order set (OS) at an independent academic health care system. METHODS: Penicillin/cephalosporin receipt (percentage of inpatients receiving full doses) and alternative antibiotic use (days of therapy per 1000 patient-days [DOT/1000PD]) were compared over 3 periods before (February 1, 2017, to January 31, 2018) and after guideline implementation (February 1, 2018, to January 31, 2019), and after OS implementation (February 1, 2019, to January 31, 2020) among inpatients with PCAAL admitted on medical services with access to guideline/OS and education (Medical-PCAAL, n = 8721), surgical services with access to guideline/OS without education (Surgical-PCAAL, n = 5069), and obstetrics/gynecology services without interventions (Ob/Gyn-PCAAL, n = 798) and inpatients without PCAAL admitted on the same services (Medical-No-PCAAL, n = 50,840; Surgical-No-PCAAL, n = 29,845; Ob/Gyn-No-PCAAL, n = 6109). χ2 tests were used to compare categorical variables, and analysis of variance was used to compare continuous and interrupted time series analyses (ITSA) to investigate the guideline/OS implementation effect on penicillin/cephalosporin receipt. RESULTS: In the Medical-PCAAL group, penicillin/cephalosporin receipt increased (58%-68%, P < .001), specifically for cefazolin (8%-11%, P = .02) and third- to fifth-generation cephalosporins (43%-48%, P = .04), and aztreonam use decreased (12 DOT/1000PD, P = .03). In the Medical-No-PCAAL group, penicillin/cephalosporin receipt increased (88%-90%, P = .004), specifically for penicillin (40%-44%, P < .001), without changes in aztreonam use. Significant changes were not observed in these outcomes on surgical or obstetrics/gynecology services. Per ITSA, guideline/OS implementation was associated with increased penicillin/cephalosporin receipt in the Medical-PCAAL group only. CONCLUSION: Guideline and OS implementation was associated with improved antibiotic stewardship on inpatient services that also received allergy education.


Drug Hypersensitivity , Hypersensitivity , Humans , Anti-Bacterial Agents/adverse effects , beta-Lactams/adverse effects , Inpatients , Aztreonam , Penicillins/adverse effects , Cephalosporins/therapeutic use , Cephalosporins/adverse effects , Drug Hypersensitivity/drug therapy , Hypersensitivity/drug therapy , Retrospective Studies
2.
Lancet Planet Health ; 7(5): e381-e386, 2023 05.
Article En | MEDLINE | ID: mdl-37164514

BACKGROUND: Large-scale wildfires in California, USA, are increasing in both size and frequency, with substantial health consequences. The capacity for wildfire smoke to displace microbes and cause clinically significant fungal infections is poorly understood. We aimed to determine whether exposure to wildfire smoke was associated with an increased risk of hospital admissions for systemic fungal infections. METHODS: In this population-based, retrospective study, we used hospital administrative data from 22 hospitals in California, USA, to analyse the association between wildfire smoke exposure and monthly hospital admissions for aspergillosis and coccidioidomycosis. We included hospitals that were members of the Vizient Clinical Data Base or Resource Manager during the study and excluded those that did not have complete reporting into Vizient during the study period. Smoke exposure was estimated using satellite-imaged smoke plumes in the hospital county. Incident rate ratios were calculated for all infection types 1 month and 3 months after smoke exposure. FINDINGS: Between Oct 1, 2014, and May 31, 2018, there were a median of 1638 annual admissions per hospital in the study sample. Individual patient demographics were not collected. We did not observe an association between smoke exposure and rate of hospital admission for aspergillosis. However, hospital admission for coccidioidomycosis increased by 20% (95% CI 5-38) in the month following any smoke exposure. Hospital admission increased by 2% (0-4) for every day that there had been smoke exposure in the previous month, after adjustment for temperature and temporal trend. Similar results were obtained with smoke exposure data from the 3 months before admission. INTERPRETATION: In the months following wildfire smoke exposure, California hospitals saw increased coccidioidomycosis infections. Given the projected increase in California wildfires and their expansion in endemic territories of soil-dwelling fungi, the ability for wildfire smoke to carry microbes and cause human disease warrants further research. FUNDING: None.


Aspergillosis , Coccidioidomycosis , Mycoses , Wildfires , Humans , Particulate Matter/adverse effects , Retrospective Studies , Coccidioidomycosis/chemically induced , Environmental Exposure/adverse effects , Smoke/adverse effects , California/epidemiology , Mycoses/epidemiology , Mycoses/chemically induced , Aspergillosis/chemically induced
3.
BMJ Case Rep ; 13(4)2020 Apr 29.
Article En | MEDLINE | ID: mdl-32354764

We describe a case of opportunistic coinfections with Coccidioides immitis and Pneumocystis jirovecii following treatment with idelalisib, a phosphoinositide 3-kinase inhibitor, for chronic lymphocytic leukaemia. This is the first case of pulmonary coccidioidomycosis reported in association with idelalisib. We review challenges related to diagnosis of opportunistic infections in this context. This report illustrates (1) the uncommon occurrence of two opportunistic infections concurrently or in rapid succession, (2) the importance of maintaining a broad differential diagnosis in the setting of an atypical imaging finding, slow clinical response or when immunomodulatory drugs are used, and (3) the challenges associated with non-invasive serological testing in individuals with haematological malignancy on immunomodulatory therapy.


Antineoplastic Agents/adverse effects , Coccidioidomycosis/diagnosis , Immunocompromised Host , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/diagnosis , Purines/adverse effects , Quinazolinones/adverse effects , Aged , Coccidioides/isolation & purification , Coccidioidomycosis/complications , Coccidioidomycosis/drug therapy , Coinfection , Diagnosis, Differential , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Male , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/drug therapy , Tomography, X-Ray Computed
5.
Open Forum Infect Dis ; 6(4): ofz134, 2019 Apr.
Article En | MEDLINE | ID: mdl-31024974

Bergeyella cardium is a new species in the family Flavobacteriaceae that was recently described in 3 cases of native valve infective endocarditis. We report the first case of B. cardium prosthetic valve endocarditis, provide the first draft genome of this species, and review the microbiologic characteristics of this emerging pathogen.

6.
Dermatol Clin ; 30(3): 369-76, 2012 Jul.
Article En | MEDLINE | ID: mdl-22800545

Total cumulative sun exposure is associated with the development of squamous cell and basal cell cancers, whereas intense intermittent sun exposure is associated with the development of melanoma. Exposure to UV radiation is the only known modifiable cause of melanoma, but the role of sunscreen in melanoma prevention remains somewhat controversial. This article discusses how UV radiation contributes to the pathogenesis of melanoma, how sunscreen modulates the action of UV radiation on the skin, and the effect of sunscreen on the risk of developing melanoma. A review of available sunscreen agents and their sun-protective properties is also included.


Melanoma/prevention & control , Skin Neoplasms/prevention & control , Sunburn/prevention & control , Sunlight/adverse effects , Sunscreening Agents , Ultraviolet Rays/adverse effects , Humans , Melanoma/etiology , Risk , Risk Reduction Behavior , Skin Neoplasms/etiology , Sunburn/complications , Sunscreening Agents/chemistry , Sunscreening Agents/classification , Ultraviolet Rays/classification
...